Exploratory analysis of brentuximab vedotin plus CHP (A plus CHP) as frontline treatment for patients with CD30-expressing PERIPHERAL T-cell lymphomas (Echelon-2): impact of consolidative stem cell transplant
Trneny, M. Savage, K. J. Horwitz, S. M. Advani, R. Christensen, J. H. Domingo-Domenech, E. Rossi, G. Morschhauser, F. Alpdogan, O. Suh, C.
Trneny, M.
Savage, K. J.
Horwitz, S. M.
Advani, R.
Christensen, J. H.
Domingo-Domenech, E.
Rossi, G.
Morschhauser, F.
Alpdogan, O.
Suh, C.
Citations
Altmetric:
Abstract
Background: ECHELON-2 (NCT01777152) demonstrated
significantly longer progression-free survival (PFS) and
overall survival with brentuximab vedotin plus cyclophosphamide,
doxorubicin and prednisone (A+CHP) versus
cyclophosphamide, doxorubicin, vincristine and prednisone
(CHOP) as frontline treatment for patients with sALCL
or other CD30-expressing PTCL. Patients could have
received consolidative stem cell transplant (SCT) after
treatment at the discretion of the treating investigator.
Only 22% (50/226) of all patients treated with A+CHP
underwent SCT. We present outcomes from an
exploratory analysis of patients in complete remission (CR)
following A+CHP who received an SCT and those who
did not.
Methods: CR rate was defined at the end of treatment
(EOT) by independent review per the Revised Response
Criteria for Malignant Lymphoma. ALK+ sALCL patients
were excluded. Consolidative transplant was not considered
a PFS event. Univariate analysis of SCT versus no SCT and multivariate analyses adjusting for region and age were
performed.
Results: 67% (76/113) of A+CHP-treated patients with
ALK- sALCL were in CR at EOT; 36% (27/76) of them
received SCT. Patients who underwent SCT were younger
than those without (median age [range]: 50 years [18-68]
versus 59 [20-85] years). Median PFS for patients with SCT
was not reached (95% CI: 36.57, not estimable [NE]) versus
55.66 months (95% CI: 23.72, 55.66) for patients without
SCT. 59% (38/64) of A+CHP-treated patients with nonsALCL
were in CR at EOT; 29% (11/38) of them received
SCT. Patients who underwent SCT were younger than those
without (median age [range] 57 years [35-73] versus 66
years [49-77]). Median PFS for patients who did and did not
receive SCT was not reached (95% CI: 20.70, NE) versus
33.22 months (95% CI: 8.08, NE), respectively.
Before treatment, the intent to transplant in Asian
countries among ALK- sALCL and non-ALCL patients
was less frequent compared to non-Asian countries (13%
and 29% versus 49% and 57%, respectively). SCT use was
also less frequent in Asia (13% and 12%) versus non-Asian
countries (32% and 23%). Standard PFS and multivariate
proportional hazards regression analyses favoured SCT use
in PTCL patients in CR after A+CHP
Authors
Description
Date
2020
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Trneny M, Savage KJ, Horwitz SM, Advani R, Christensen JH, Domingo-Domenech E, et al. Exploratory analysis of brentuximab vedotin plus CHP (A plus CHP) as frontline treatment for patients with CD30-expressing PERIPHERAL T-cell lymphomas (Echelon-2): impact of consolidative stem cell transplant. Bone Marrow Transplantation. 2020;55(SUPPL 1):115-6.